Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: A focus on vorinostat and panobinostat

Salma Afifi, Angela Michael, Mahshid Azimi, Mabel Rodriguez, Nikoletta Lendvai, Ola Landgren

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Multiple myeloma is a neoplastic plasma cell disorder that is characterized by clonal proliferation of plasma cells in the bone marrow, monoclonal protein in the blood and/or urine, and associated organ dysfunction and biomarkers. There have been multiple recent advances in the relapsed and refractory setting. Major steps forward include the introduction of proteasome inhibitors (bortezomib and carfilzomib) and immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide) in various combinations. These drugs have changed the management of multiple myeloma and have extended overall survival in the past decade. Established curative therapy is not yet available for patients diagnosed with multiple myeloma, supporting the development of new treatment targets. Histone deacetylase inhibitors have multiple proposed mechanisms of action in the treatment of multiple myeloma. Both vorinostat and panobinostat have demonstrated some activity against multiple myeloma, and due to the benefits reported with panobinostat, the U.S. Food and Drug Administration has recently approved the drug for the treatment of relapsed and refractory multiple myeloma. In this article, we describe the pharmacology, efficacy, and toxicity profile of vorinostat and panobinostat and their possible place in therapy.

Original languageEnglish (US)
Pages (from-to)1173-1188
Number of pages16
JournalPharmacotherapy
Volume35
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Keywords

  • HDAC
  • histone deacetylase inhibitors
  • multiple myeloma
  • panobinostat
  • refractory
  • relapsed
  • treatment
  • vorinostat

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Role of histone deacetylase inhibitors in relapsed refractory multiple myeloma: A focus on vorinostat and panobinostat'. Together they form a unique fingerprint.

Cite this